Abbott has announced new real-world evidence showing that completion of multitarget stool DNA (mt-sDNA) screening was associated with approximately 54% lower colorectal cancer incidence and 45% lower odds of death following a colorectal cancer diagnosis.
The findings are among 13 abstracts highlighting new colorectal cancer screening research being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place 9-14 October in Nashville.
Among the research presented at ACG are two large real-world studies that provide novel data regarding associations between completion of multitarget stool DNA (mt-sDNA) screening and important long-term colorectal cancer outcomes.
In a nationwide cohort of more than 2.5 million average-risk adults, researchers found that completing mt-sDNA screening was associated with an approximately 54% lower adjusted incidence rate of colorectal cancer compared with not completing the test. The association remained consistent across sensitivity analyses.
A separate population-based case-control study of 5,745 people diagnosed with colorectal cancer found that completing mt-sDNA screening within the five years before diagnosis was associated with 45% lower odds of death after diagnosis compared to those who did not complete an mt-sDNA test during that period. The association was observed across all racial and ethnic groups examined.
Together, the findings add to the growing body of real-world evidence examining longer-term outcomes associated with mt-sDNA screening, which has been used to screen for colorectal cancer more than 23 million times since the Cologuard test launched in 2014.
The total research presence includes two oral presentations and 11 poster presentations spanning real-world clinical outcomes, sustained screening adherence, comparative effectiveness, test performance, health economics and patient costs. The findings add to the evidence supporting multitarget stool DNA (mt-sDNA) screening with Cologuard and Cologuard Plus and provide new insights into how colorectal cancer screening strategies perform in real-world populations.
